Chinese Medicine最新文献

{"title":"Utilization of natural products in diverse pathogeneses of diseases associated with single or double DNA strand damage repair.","authors":"Jiali Liang, Wanqing Liu, Tong Zhang, Dean Guo, Jiyu Gong, Zizhao Yang","doi":"10.1186/s13020-025-01089-y","DOIUrl":"https://doi.org/10.1186/s13020-025-01089-y","url":null,"abstract":"<p><p>The appearance of DNA damage often involves the participation of related enzymes, which can affect the onset and development of various diseases. Several natural active compounds have been found to efficiently adjust the activity of crucial enzymes associated with single or double-strand DNA damage, thus demonstrating their promise in treating diseases. This paper provides an in-depth examination and summary of these modulation mechanisms, leading to a thorough review of the subject. The connection between natural active compounds and disease development is explored through an analysis of the structural characteristics of these compounds. By reviewing how different scholarly sources describe identical structures using varied terminology, this study also delves into their effects on enzyme regulation. This review offers an in-depth examination of how natural active compounds can potentially be used therapeutically to influence key enzyme activities or expression levels, which in turn can affect the process of DNA damage repair (DDR). These natural compounds have been shown to not only reduce the occurrence of DNA damage but also boost the efficiency of repair processes, presenting new therapeutic opportunities for conditions such as cancer and other disease pathologies. Future research should focus on clarifying the exact mechanisms of these compounds to maximize their clinical utility and support the creation of novel approaches for disease prevention and treatment.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"46"},"PeriodicalIF":5.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological effects of bile acids on polycystic ovary syndrome via the regulation of chemerin.","authors":"Tian-Tian Tong, Long-Bo Bai, Lee-Fong Yau, Jiu-Yan Li, Hao Huang, Zhi-Hong Jiang","doi":"10.1186/s13020-025-01078-1","DOIUrl":"10.1186/s13020-025-01078-1","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) poses significant health risks for women of reproductive age, and conventional treatments typically involve anti-hormonal interventions or surgical procedures, which often lead to lifelong medication cycles and potential side effects. Bile acids have been applied in the treatment of PCOS-related conditions, including obesity and type 2 diabetes. This study aimed to investigate the effects of bile acids on a PCOS rat model and explore the underlying mechanisms involved.</p><p><strong>Methods: </strong>Morphological index evaluation, histopathological examination, and hormonal profiling were employed to assess the therapeutic effects of eight bile acids. A targeted proteomics was utilized to characterize and quantify highly homologous chemerin isoforms in rat serum. Network pharmacology analysis was conducted to identify potential targets and molecular mechanisms involved. Molecular docking was performed to evaluate the affinity between bile acids and farnesoid X receptor (FXR).</p><p><strong>Results: </strong>Five of the eight bile acids markedly restored morphological indices, histopathological manifestations, hormonal imbalances, and chemerin isoform dysregulation. Notably, the therapeutic effects of TDCA and GUDCA on PCOS were reported for the first time. As the severity of the disease decreased, chemerin-157S was negatively correlated with progesterone (P4), estradiol (E2), antral follicles, and corpus luteum, respectively. Several chemerin-associated pathways have been identified via network pharmacology analysis. Additionally, a 7β-hydroxy group carried on the steroid skeleton of bile acids has been found to exhibit positive therapeutic efficacy in PCOS.</p><p><strong>Conclusions: </strong>Downregulating chemerin levels via specific bile acids may be a promising therapeutic strategy for PCOS patients.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"45"},"PeriodicalIF":5.3,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astragaloside IV accelerates hematopoietic reconstruction by improving the AMPK/PGC1α-mediated mitochondrial function in hematopoietic stem cells.","authors":"Ling Zhang, Wanqi Xu, Yueying Zeng, Long Wang, Jiesi Luo, Xiaogang Zhou, Qibing Mei, Dalian Qin, Anguo Wu, Jianming Wu, Feihong Huang","doi":"10.1186/s13020-025-01092-3","DOIUrl":"10.1186/s13020-025-01092-3","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy can damage hematopoietic stem cells (HSC) in bone marrow, leading to impaired hematopoietic function. Current treatments mainly target differentiated hematopoietic progenitor cells, which may accelerate their depletion. Astragaloside IV (AS-IV), derived from Astragalus membranaceus, shows potential in hematopoiesis, but its direct effects on HSC remain unclear.</p><p><strong>Methods: </strong>The study employed both in vitro and in vivo approaches. In vitro experiments utilized K562 cells and mouse bone marrow nucleated cells (BMNCs) to evaluate AS-IV's effects on cell proliferation and mitochondrial function. In vivo studies involved a 4.0 Gy total body irradiation mouse model treated with different doses of AS-IV (50 mg/kg and 100 mg/kg). The mechanism of action was investigated through Western blot, flow cytometry, and metabolomics analyses. The AMPK/PGC1α pathway regulation was verified using AMPK inhibitors and mutant plasmid, with molecular docking confirming AS-IV's direct binding to AMPK.</p><p><strong>Results: </strong>In vitro studies demonstrated that AS-IV significantly promoted the proliferation of K562 cells and BMNC while enhancing their mitochondrial membrane potential, mitochondrial mass, and ATP production. In the irradiated mouse model, AS-IV treatment led to significant improvements in peripheral blood cell counts, including white blood cells, red blood cells, and hemoglobin levels. Further investigation revealed that AS-IV increased the proportion of HSC in both bone marrow and spleen while improving their mitochondrial function. Transcriptomic sequencing and Western blot analysis identified the AMPK/PGC1α signaling pathway as the key mechanism underlying AS-IV-mediated mitochondrial enhancement. These findings were validated through pharmacological inhibition of AMPK and AMPK^K45R mutation experiments.</p><p><strong>Conclusion: </strong>AS-IV accelerates hematopoietic reconstruction following radiation injury via activation of the AMPK/PGC1α signaling pathway, which enhances HSC mitochondrial function.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"44"},"PeriodicalIF":5.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing Chinese medicine granule placebo with a machine learning four-color model.","authors":"Tingting Teng, Jingze Zhang, Peiqi Miao, Lipeng Liang, Xinbo Song, Dailin Liu, Junhua Zhang","doi":"10.1186/s13020-024-01055-0","DOIUrl":"10.1186/s13020-024-01055-0","url":null,"abstract":"<p><p>With the development of new Chinese medicines and the need for clinical double-blind experiments, the use of placebos in Chinese medicine is becoming increasingly important. However, due to the diverse colors and complex color gamut of these particles, existing simulation methods rely on manual comparison and color mixing, leading to high subjectivity and errors. This study addresses this issue by developing a prediction model to accurately simulate the colors of Chinese medicine granules. In this study, 52 commercially available herbal particles were collected. And more than 320 simulated granules were prepared using fillers and four pigments (lemon yellow, carmine, indigo and caramel colors). Their RGB colors were collected using visible light imaging. A granule color prediction model was constructed by machine learning. First, the best clustering model was obtained by optimising the k-value of the Kmeans model. Subsequently, multiple regression models, including Gradient Boosting Regression (GBR), Support Vector Regression (SVR), and Random Forest, were evaluated through network search and cross-validation methods. Among these models, the average R² of the random forest model reached 0.9249, outperforming other models. The prediction model accurately simulated the color of Chinese medicine granules, with an average color difference (ΔE) of 2.7734 and a high RGB value cosine similarity of 0.9999, alongside a 0.9366 similarity in artificial color scoring. This study introduces an innovative approach for the rapid and accurate prediction of granule colors, facilitating the development of clinically applicable placebos in traditional Chinese medicine.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"43"},"PeriodicalIF":5.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative network pharmacology, transcriptomics, and proteomics reveal the material basis and mechanism of the Shen Qing Weichang Formula against gastric cancer.","authors":"Yi Wang, Xiaoyu Sun, Mingming Ren, Fangqi Ma, Ruohan Zhao, Xiaohong Zhu, Yan Xu, Nida Cao, Yuanyuan Chen, Yongfu Pan, Aiguang Zhao","doi":"10.1186/s13020-025-01091-4","DOIUrl":"https://doi.org/10.1186/s13020-025-01091-4","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a common malignancy with poor prognosis and lack of efficient therapeutic methods. Shen Qing Weichang Formula (SQWCF) is a patented traditional herbal prescription for GC, but its efficacy and underlying mechanism remains to be clarified.</p><p><strong>Purpose: </strong>To explore the efficacy and potential mechanism of SQWCF in treating GC.</p><p><strong>Methods: </strong>A subcutaneous transplantation tumor model of human GC was established for assessing SQWCF's efficacy and safety. A comprehensive strategy integrating mass spectrometry, network pharmacology, omics analysis, and bioinformatic methods was adopted to explore the core components, key targets, and potential mechanism of SQWCF in treating GC. Molecular docking, immunohistochemistry, quantitative real-time PCR, and western blot were applied to validation.</p><p><strong>Results: </strong>In the mouse model of GC, SQWCF effectively suppressed the GC growth without evident toxicity and enhanced the therapeutic efficacy of paclitaxel. Network pharmacology and molecular docking based on mass spectrometry showed that key targets (CASP3, TP53, Bcl-2, and AKT1) and core active components (Calycosin, Glycitein, Liquiritigenin, Hesperetin, and Eriodictyol) involved in the anti-GC effect of SQWCF had stable binding affinity, of which AKT1 ranked the top in the affinity. Validation based on network pharmacology and omics analysis confirmed that PI3K-AKT and MAPK signaling pathways, as well as downstream apoptosis pathway, explained the therapeutic effects of SQWCF on GC. In addition, family with sequence similarity 81 member A (FAM81A) was identified as a novel biomarker of GC that was aberrantly highly expressed in GC and associated with poor prognosis by bioinformatic analysis, and was an effector target of SQWCF at both mRNA and protein levels.</p><p><strong>Conclusion: </strong>This study uncovers a synergistic multi-component, multi-target, and multi-pathway regulatory mechanism of SQWCF in treating GC comprehensively, emphasizing its potential for therapeutic use and providing new insights into GC treatment.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"42"},"PeriodicalIF":5.3,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aurantio-obtusin improves obesity and protects hepatic inflammation by rescuing mitochondrial damage in overwhelmed brown adipose tissue.","authors":"Ruiyu Wu, Runping Liu, Ranyun Chen, Yijie Li, Xiaoyong Xue, Yinhao Zhang, Fanghong Li, Jiaorong Qu, Lingling Qin, Chen Wang, Xiaojiaoyang Li","doi":"10.1186/s13020-025-01097-y","DOIUrl":"10.1186/s13020-025-01097-y","url":null,"abstract":"<p><strong>Background: </strong>Obesity is frequently linked to chronic systamic inflammation and presents significant challenges to public health. Aurantio-obtusin (AO) boosted the brown adipose tissue (BAT) thermogenesis in diet-induced obesity. However, the specific mechanisms by which injured mitochondria-related damage signals derived from overwhelmed BAT can transmit to liver and exacerbate metabolic disorders and whether AO can reverse this process remain unknown.</p><p><strong>Materials and methods: </strong>After applying high-fat diet and glucose-fructose water (HFHS)-induced obesity mice, different BAT transplant procedures and primary BAT adipocytes, we investigated the anti-obesity effects and mechanism of AO through RNA sequencing and biology techniques.</p><p><strong>Results: </strong>AO improved whole-body lipid accumulation, mitochondrial metabolism in BAT and hepatic inflammation in HFHS-induced obesity mice. Interscapular transplant of BAT-derived from obese donor mice triggered hepatic inflammation of chow diet-fed recipient mice, which was protected by AO. Furthermore, the transplantation of BAT-derived from AO-treated mice protected hepatic inflammation in obese mice. In vivo and in lipid-challenged primary BAT adipocytes, AO decreased kexin type 9 (PCSK9), prevented mPTP opening and mitochondrial DNA (mtDNA) release in extracellular vesicles (EVs) manner by inhibiting the acetylation of cyclophilin D associated with adenine nucleotide translocase, suppressing oligomerization of voltage-dependent anion channel 1 and activating mitophagy. Ultimately, AO inhibited mtDNA-containing EVs-induced cyclic GMP-AMP synthase/stimulator of interferon genes (STING) activation and hepatic inflammation, which was confirmed by Sting^-/- mice.</p><p><strong>Conclusion: </strong>AO not only improves thermogenesis and mitochondrial function of BAT but also prevents liver inflammation by repairing mitochondrial function and blocking the transfer of mtDNA from BAT to the liver.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"41"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization.","authors":"Yu Yuan, Lulu Yu, Chenghao Bi, Liping Huang, Buda Su, Jiaxuan Nie, Zhiying Dou, Shenshen Yang, Yubo Li","doi":"10.1186/s13020-025-01075-4","DOIUrl":"10.1186/s13020-025-01075-4","url":null,"abstract":"<p><p>In the past, the drug research and development has predominantly followed a \"single target, single disease\" model. However, clinical data show that single-target drugs are difficult to interfere with the complete disease network, are prone to develop drug resistance and low safety in clinical use. The proposal of multi-target drug therapy (also known as \"cocktail therapy\") provides a new approach for drug discovery, which can affect the disease and reduce adverse reactions by regulating multiple targets. Natural products are an important source for multi-target innovative drug development, and more than half of approved small molecule drugs are related to natural products. However, there are many challenges in the development process of natural products, such as active drug screening, target identification and preclinical dosage optimization. Therefore, how to develop multi-target drugs with good drug resistance from natural products has always been a challenge. This article summarizes the applications and shortcomings of related technologies such as natural product bioactivity screening, clarify the mode of action of the drug (direct/indirect target), and preclinical dose optimization. Moreover, in response to the challenges faced by natural products in the development process and the trend of interdisciplinary and multi-technology integration, and a multi-target drug development strategy of \"active substances - drug action mode - drug optimization\" is proposed to solve the key challenges in the development of natural products from multiple dimensions and levels.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"40"},"PeriodicalIF":5.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New advances in Traditional Chinese Medicine interventions for epilepsy: where are we and what do we know?","authors":"Minjuan Sun, Xiaoyun Qiu, Zhijian Yuan, Cenglin Xu, Zhong Chen","doi":"10.1186/s13020-025-01088-z","DOIUrl":"10.1186/s13020-025-01088-z","url":null,"abstract":"<p><p>Epilepsy, one of the most common neurological diseases, affects more than 70 million people worldwide. Anti-seizure drugs targeting membrane ion channels or GABAergic neurotransmission are the first choices for controlling seizures, whereas the high incidence of pharmacoresistance and adverse effects largely restrict the availability of current anti-seizure drugs (ASDs). Traditional Chinese Medicine (TCM) has shown historical evidence-based therapeutic effects for neurological diseases including epilepsy. But until the late 1990s, great efforts in both clinical and experimental fields advanced TCM interventions for epilepsy from evidence-based practices to more systematic neuropharmacological significance, and show new lights on preferable management of epilepsy in the last decade. This review summarized the advances of applying TCM interventions (ranging from herbal medicines and their active ingredients to other strategies such as acupuncture) for epilepsy, followed by associated mechanism theories. The therapeutic potential of TCM interventions for epilepsy as well as its comorbidities turns from somehow debatable to hopeful. Finally, some prospects and directions were proposed to drive further clinical translational research. The future directions of TCM should aim at not only deriving specific anti-epileptic molecules but also illustrating more precise mechanisms with the assistance of advanced multifaceted experimental tools.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"37"},"PeriodicalIF":5.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shengui Sansheng San alleviates the worsening of blood-brain barrier integrity resulted from delayed tPA administration through VIP/VIPR1 pathway.","authors":"Jiacheng Hu, Yiyang Li, Xingping Quan, Yan Han, Jinfen Chen, Mengchen Yuan, Ying Chen, Manfei Zhou, Enze Yu, Jiahao Zhou, Dawei Wang, Ruibing Wang, Yonghua Zhao","doi":"10.1186/s13020-025-01079-0","DOIUrl":"10.1186/s13020-025-01079-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Intravenous tissue plasminogen activator (tPA) is currently the only FDA-approved thrombolytic therapy for acute ischemic stroke (AIS), however, relative narrow therapeutic time window (within 4.5 h of AIS onset) and high risk of hemorrhagic transformation due to blood-brain barrier (BBB) disruption limit tPA therapeutic benefits for patients. In this study, we extended the time window of tPA administration (5 h after the occurrence of AIS) and investigated whether Chinese medicine classical formula Shengui Sansheng San (SSS) administration was able to alleviate BBB integrity worsening, and the mechanism was related to vasoactive intestinal peptide (VIP)/ VIP receptor 1 (VIPR1) pathway.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;SSS was extracted using aqueous heating method and SFE-CO&lt;sub&gt;2&lt;/sub&gt; technology, and quality control was performed using UHPLC/MS analysis. Male C57BL/6 mice were suffered from middle cerebral artery occlusion (MCAo), followed by the removal of a silicone filament after 5 h, then, t-PA was administered via tail vein injection at once, along with SSS administration by gavage. Hemoglobin levels and Evans blue leakage were measured to assess brain hemorrhagic transformation and BBB permeability, respectively. Transmission electron microscope (TEM) was utilized to present brain microvascular endothelial cells (BMECs) tight junction morphology. TTC staining and laser speckle contrast imaging were employed for infarct volume and cerebral blood flow measurements. The modified neurological severity score (mNSS) test was conducted to evaluate neurological function. The expressions of VIP, VIPR1, ZO-1, Occludin, Lectin, GFAP, NeuN were detected by immunofluorescence staining or western blotting. In vitro, bEnd.3 and N2a cells were insulted by oxygen-glucose deprivation (OGD), and VIPR1 siRNA, and VIP shRNA transfection were respectively performed, and the molecular docking was applied to verify the SSS in-serum active compounds interacted with VIPR1. The transwell system was utilized to detect OGD-insulted BMECs permeability.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;SSS treatment significantly reduced the infarct area, cerebral hemorrhage, and neurological deficits, and enhanced cerebral blood flow in AIS mice received intravenous tPA beyond 4.5 h time window. Simultaneously, the permeability of BBB declined, with increased expressions of tight junction proteins ZO-1, and Occludin and proper BMECs tight junction morphology, and it suggested that VIP was released by neurons rather than astrocytes or BMECs. It also showed high expressions of VIP and VIPR1 in the penumbra area. The inhibition of VIP in N2a cells or VIPR1 in bEnd.3 cells abolished the viability and integrity of OGD-insulted bEnd.3 cells treated by tPA after SSS-containing serum administration, and the SSS in-serum active compounds were proved have high affinity to VIPR1 by molecular docking.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;SSS alleviates the worsening o","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"38"},"PeriodicalIF":5.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reunderstanding the classical prescription Banxia Xiexin Decoction: new perspectives from a comprehensive review of clinical research and pharmacological studies.","authors":"Chang Liu, Pengwei Gao, Xiaoying Liu, Min Kuang, Haoran Xu, Yangming Wu, Wenjun Liu, Shengpeng Wang","doi":"10.1186/s13020-025-01087-0","DOIUrl":"10.1186/s13020-025-01087-0","url":null,"abstract":"<p><p>Classical prescriptions of Chinese medicine represent the crystallized wisdom of millennia of clinical practice, enduring as cornerstones of therapeutic intervention due to their demonstrated efficacy across generations. Their evolving role in modern healthcare systems reflects shifting disease patterns, scientific advancements, and global health priorities. Banxia Xiexin Decoction (BXD), formulated by Zhang Zhongjing in the Treatise on Febrile and Miscellaneous Diseases (Shanghanlun), is a time-honored classical prescription renowned for its therapeutic versatility in managing gastrointestinal disorders, both in China and internationally. Recent advancements in clinical research and pharmacological studies on BXD underscore the necessity for a comprehensive bibliometric analysis to summarize and elucidate its specific clinical benefits. Through an extensive literature review of publications from the Web of Science, PubMed, Scopus, and the China National Knowledge Infrastructure (CNKI) between 1997 and 2024, 11 major categories of clinical applications for BXD were identified, along with an analysis of the potential pharmacological mechanisms, such as chronic gastritis, functional dyspepsia, and inflammatory bowel disease. We believe this review will provide new insights into the understanding of clinical value of BXD and identify potential future perspectives for its research and development.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"20 1","pages":"39"},"PeriodicalIF":5.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}